April 24, 2020 / 11:16 AM / a month ago

BRIEF-Oryzon Gets Approval To Conduct Phase II Clinical Trial With Vafidemstat In COVID-19 Patients

April 24 (Reuters) - Oryzon Genomics SA:

* RECEIVES APPROVAL FROM SPANISH DRUG AGENCY (AEMPS) TO CONDUCT A PHASE II CLINICAL TRIAL WITH VAFIDEMSTAT IN SEVERELY ILL COVID-19 PATIENTS

* SAYS AIM OF STUDY IS TO EXPLORE A THERAPEUTIC INTERVENTION TO PREVENT PROGRESSION TO ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS)

* ARDS IS ONE OF THE MAIN CAUSES OF DEATH IN SEVERE COVID-19 PATIENTS Source text: bit.ly/2Kt9rWf Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below